Promising cholesterol drug fails to prevent heart attacks or stroke

• Pelacarsen, a promising drug for an inherited heart risk, failed to show any measurable impact on heart attack or stroke.
• The drug was expected to significantly lower a dangerous form of cholesterol.
• The clinical trial results were surprising and disappointing to doctors and researchers.
• Novartis, the pharmaceutical company behind the drug, has abandoned further development of Pelacarsen.
• The failure of Pelacarsen highlights the unpredictable nature of drug development and clinical trials.